## Test-Negative 3+ vs 2 Dose Non-Matched Severe Disease VE

Design	Control	Start Quarter	Adjusted	n		VE	95% CI
1	1	Q4 2021	N	87839	<del></del>	0.259	(0.144,0.359)
2	2	Q4 2021	N	79643	<del></del>	0.289	(0.178, 0.385)
3	3	Q4 2021	N	8936	<del></del>	0.284	(0.174,0.395)
4	1	Q4 2021	Υ	87839	<b>⊢</b>	→ 0.508	(0.423, 0.581)
5	2	Q4 2021	Υ	79643	l——	0.561	(0.477, 0.631)
6	3	Q4 2021	Υ	8936	<b>⊢</b>	0.607	(0.511,0.702)
7	1	Q1 2022	N	58220		0.350	(0.230, 0.451)
8	2	Q1 2022	N	52443	<del> 1</del>	0.381	(0.267, 0.477)
9	3	Q1 2022	N	6356	<del></del>	0.383	(0.265, 0.501)
10	1	Q1 2022	Υ	58220		0.425	(0.313,0.519)
11	2	Q1 2022	Υ	52443		→ 0.482	(0.370, 0.574)
12	3	Q1 2022	Υ	6356		0.533	(0.416,0.651)
13	1	Q2 2022	N	32530		0.108	(-0.109,0.282)
14	2	Q2 2022	N	29788	-	0.098	(-0.120,0.274)
15	3	Q2 2022	N	3130	-	0.125	(-0.114,0.363)
16	1	Q2 2022	Υ	32530		0.257	(0.067, 0.408)
17	2	Q2 2022	Υ	29788	-	0.292	(0.092, 0.447)
18	3	Q2 2022	Υ	3130	-	0.167	(-0.093, 0.427)
19	1	Q3 2022	N	16713	-	0.075	(-0.210,0.292)
20	2	Q3 2022	N	15480	-	0.070	(-0.217,0.289)
21	3	Q3 2022	N	1485	-	0.093	(-0.212, 0.398)
22	1	Q3 2022	Υ	16713	-	0.249	(0.004, 0.434)
23	2	Q3 2022	Υ	15480	-	0.312	(0.064, 0.494)
24	3	Q3 2022	Υ	1485		0.185	(-0.131,0.502)
					0.25 0.4 0.04 0.2 0.2 0.4 0.5	0.6.0.7	
					-0.25 -0.1 0 0.1 0.2 0.3 0.4 0.5	0.0 0.7	